anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The aim of this study is to evaluate the ability of infrared wavenumber of calculus to predict postoperative infection in patients with upper urinary tract calculus (UUTC), and to establish a predictive model based on this. From March 2018 to March 2023, 480 UUTC patients from Fujian Provincial Hospital were included in this study. The infrared-wavenumbers related infection score (IR-infection score) was constructed by univariate analysis, multicollinearity screening, and Lasso analysis to predict postoperative infection. Continually, the Delong test was used to compare the predictive power between the IR-infection score and traditional indicators. Afterward, we performed urine metagene sequencing and stone culture to prove the correlation between calculus toxicity and IR-infection score. Finally, logistic regression was used to build a nomogram. IR-infection score composed of four independent wavenumbers could precisely predict postoperative infection (AUCvalidation cohort = 0.707) and sepsis (AUCvalidation cohort = 0.824). IR-infection score had better predictive ability than commonly used clinical indicators. Moreover, metagenomics sequencing and calculus culture confirmed the correlation between IR-infection score and calculus toxicity (all P < 0.05). The nomogram based on the IR-infection score had high predictive power (all AUCs > 0.803). Our study first developed a novel infrared spectroscopy marker and nomogram, which can help urologists better predict postoperative infection in UUTC patients.
This is a randomized, double-blind, placebo-controlled, cross-over experimental design. Participants will be asked to complete 3 visits to the laboratory; one informed consent/screening visit and 2 study visits. On study visit days, participants will report to the laboratory following a 12-hour fast, and 24-hour abstention from exercise, caffeine, and alcohol. During the study visits, participants will ingest either a placebo or one dose of mirabegron prior to entering our water immersion tank. Then they will be instrumented for the measurement of heart rate (3-lead ECG), blood pressure (brachial artery auscultation), core temperature (rectal thermistor), and indices of shivering (surface mechanomyography using triaxial accelerometers at 3 anatomic sites (chest, upper back, and thigh), oxygen consumption via ventilation and expired gases, and the bedside shivering assessment scale). Thermal perceptions will be assessed using Likert scales for thermal discomfort and thermal sensation. Following 10 minutes of resting baseline measurements, infrared thermography will then be used to measure skin temperature of the supraclavicular fossa as an estimate of brown adipose tissue activation and thermal perceptions will be assessed.

The measurement of supraclavicular fossa skin temperature (infrared thermography) and thermal perceptions will be assessed every 10 minutes prior to the progressive cold-water challenge. After 30 minutes of seated rest, pre-immersion measurements of heart rate, blood pressure, core temperature, shivering, and thermal perceptions will be conducted and an infrared thermography image will be taken. Then, the water immersion tank will be filled up to the participant's neck with 35 degrees C (95 degrees F) water. Heart rate, blood pressure, core temperature, and shivering indices will be continuously measured. Infrared thermography and thermal perceptions will be obtained every 5 minutes throughout the progressive cold-water challenge. The temperature of the water will be progressively lowered by \~12 degrees C every 60 minutes until the water temperature reaches 10 degrees C (50 degrees F) or until the participant can no longer tolerate the cold or if rectal temperature reaches 35.5 degrees C (95.9 degrees F). Upon completion of the progressive cold water challenge, the water in the tank will be rapidly emptied. Participants will gently towel dry and will be able to don a circulating warm water perfused suit and/or use a mylar blanket to reestablish core temperature.

Participants will be asked to return to the laboratory after 10-14 days to repeat the experiment with the drug assignment not yet received. Each participant's order of assignment to placebo or drug ingestion (prior to the cold water challenge) over the 2 study visits will be randomly assigned.
The following are claimed: (A) prodn. of a flavano-lignan (FL) prepn. which has improved release properties compared to pure FL, comprising: (a1) prodn. of an aq.-alcoholic soln. of carriers and wetting agents, suspending an FL in this soln., and heating the resulting mixt. to boiling temp. to give a clear soln.; or (a2) suspending an FL and a wetting agent in alcohol, warming and stirring the suspension until a clear soln. is formed, treating this soln. with an aq. soln. of carriers, and heating and stirring the resulting mixt. until a clear soln. is formed; and (b) concentrating the clear soln. resulting from steps (a1) or (a2) until a coprecipitate is formed, then filtering and drying the coprecipitate. (B) Prepn. of a medicament for prophylactic and/or therapeutic treatment of liver disorders, comprising processing an FL prepn., which is in the form of a co-ppte. of an FL and at least one carrier (such as may be prepd. as described in (A) above) to a dosage form suitable for oral admin. Pref. the carrier is a water soluble sugar deriv. such as a mono- or disaccharide and/or a cellulose deriv. (such as sodium carboxymethyl starch, hydroxyethyl starch or carboxymethylcellulose), or is a linear polymer of 1-vinyl-2-pyrrolidone (such as polyvidone) for disperse systems. The wetting agent is polysorbate (such as polysorbate 80) or a sorbitan ester of a fatty acid.
The invention discloses Lactiplantibacillus plantarum ZN1 and application thereof. The strain ZN1 has stronger acid resistance and bile salt resistance, and has outstanding immunity improvement and bacteriostasis effects. The strain ZN1 has obvious inhibition effect on common gram-negative pathogenic bacteria such as salmonella, escherichia coli and the like, and gram-positive pathogenic bacteria such as clostridium perfringens, staphylococcus aureus and the like. The strain can effectively resist the influence of acidic and high-bile-salt environments and keep higher activity. The lactobacillus plantarum ZN1 strain fermentation supernatant can obviously enhance phagocytic activity of macrophages, participate in nonspecific immunity of organisms, improve the level of immune activity molecules NO released by the macrophages, and further reduce inflammatory reaction in vivo. The strain can be widely applied to the fields of foods or medicines and the like and has wide prospect.
BACKGROUND: Children with classic congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency require treatment with glucocorticoids, usually at supraphysiologic doses, to address cortisol insufficiency and reduce excess adrenal androgens. However, such treatment confers a predisposition to glucocorticoid-related complications. In 2-week phase 2 trials, patients with CAH who received crinecerfont, a new oral corticotropin-releasing factor type 1 receptor antagonist, had decreases in androstenedione levels.
METHODS: In this phase 3, multinational, randomized trial, we assigned pediatric participants with CAH, in a 2:1 ratio, to receive crinecerfont or placebo for 28 weeks. A stable glucocorticoid dose was maintained for 4 weeks, and the dose was then adjusted to a target of 8.0 to 10.0 mg per square meter of body-surface area per day (hydrocortisone dose equivalents), provided that the androstenedione level was controlled (≤120% of the baseline level or within the reference range). The primary efficacy end point was the change in the androstenedione level from baseline to week 4. A key secondary end point was the percent change in the glucocorticoid dose from baseline to week 28 while androstenedione control was maintained.
RESULTS: A total of 103 participants underwent randomization, of whom 69 were assigned to crinecerfont and 34 to placebo; 100 (97%) remained in the trial at 28 weeks. At baseline, the mean glucocorticoid dose was 16.4 mg per square meter per day, and the mean androstenedione level was 431 ng per deciliter (15.0 nmol/liter). At week 4, androstenedione was substantially reduced in the crinecerfont group (-197 ng per deciliter [-6.9 nmol/liter]) but increased in the placebo group (71 ng per deciliter [2.5 nmol/liter]) (least-squares mean difference [LSMD], -268 ng per deciliter [-9.3 nmol/liter]; P<0.001); the observed mean androstenedione value, obtained before the morning glucocorticoid dose, was 208 ng per deciliter (7.3 nmol/liter) in the crinecerfont group, as compared with 545 ng per deciliter (19.0 nmol/liter) in the placebo group. At week 28, the mean glucocorticoid dose had decreased (while androstenedione control was maintained) by 18.0% with crinecerfont but increased by 5.6% with placebo (LSMD, -23.5 percentage points; P<0.001). Headache, pyrexia, and vomiting were the most common adverse events.
CONCLUSIONS: In this phase 3 trial, crinecerfont was superior to placebo in reducing elevated androstenedione levels in pediatric participants with CAH and was also associated with a decrease in the glucocorticoid dose from supraphysiologic to physiologic levels while androstenedione control was maintained. (Funded by Neurocrine Biosciences; CAHtalyst Pediatric ClinicalTrials.gov number, NCT04806451.).
A method and system for assessing balance and posture of a subject by employing virtual reality (VR) or augmented reality (AR) headgear is provided. The system includes memory, a processor, and the VR/AR headgear, providing an immersive environment. The VR/AR headgear includes a display for providing a plurality of visual stimuli. A gyroscope and an inertial measurement unit detect head movements and body sway of the subject in response to the plurality of visual stimuli. An eye tracking unit tracks eye movement of the subject in response to the plurality of visual stimuli. A base plate with sensors can measure center of gravity of the subject in response to movements of the base plate. A machine learning model then deciphers patterns based on measurement data from the gyroscope, inertial measurement unit, eye tracking unit, and base plate. A comprehensive report pertaining to the subject's posture and balance is then generated.
Participants in the hospital-based rehabilitation group performed aerobic and strengthening exercises under the supervision of a physiotherapist/nurse/research doctor three days a week for four weeks in the cardiopulmonary rehabilitation unit. Aerobic exercise included 30-minute treadmill walking at 60-80% of the peak VO2 value obtained in the cardiopulmonary exercise test. After the end of the aerobic exercise, upper and lower extremity muscle strengthening exercises were performed with warm-up and cool-down periods using medium-tension elastic bands under the supervision of a physiotherapist. At the end of four weeks, the program was terminated and a follow-up evaluation was conducted.
PURPOSE: A pharmaceutical composition containing triterpene compound isolated from Astilbe chinensis for preventing and treating cancer is provided to reduce adhesion ability of cancer cells and proliferation of the cancer cells. CONSTITUTION: A pharmaceutical composition for preventing and treating cancer contains Astilbe chinensis extract as an active ingredient. The Astilbe chinensis extract is obtained using water, alcohol of C1-C4 or their mixture solution. The pharmaceutical composition for preventing and treating cancer contains Astilbe chinensis fraction as an active ingredient. The Astilbe chinensis fraction is obtained by suspensing the Astilbe chinensis extract in the water, fractioning with hexane or through column chromatography using mixture solvent of hexane, chloroform, and methanol as elution solution. The pharmaceutical composition for preventing and treating cancer contains triterpene compound and its pharmaceutically acceptable salt.
Gastrointestinal biofilms are matrix-enclosed, highly heterogenic and spatially organized polymicrobial communities that can cover large areas in the gastrointestinal tract. Gut microbiota dysbiosis, mucus disruption, and epithelial invasion are associated with pathogenic biofilms that have been linked to gastrointestinal disorders such as irritable bowel syndrome, inflammatory bowel diseases, gastric cancer, and colorectal cancer. Intestinal biofilms are highly prevalent in ulcerative colitis and irritable bowel syndrome patients, and most endoscopists will have observed such biofilms during colonoscopy, maybe without appreciating their biological and clinical importance. Gut biofilms have a protective extracellular matrix that renders them challenging to treat, and effective therapies are yet to be developed. This review covers gastrointestinal biofilm formation, growth, appearance and detection, biofilm architecture and signalling, human host defence mechanisms, disease and clinical relevance of biofilms, therapeutic approaches, and future perspectives. Critical knowledge gaps and open research questions regarding the biofilm's exact pathophysiological relevance and key hurdles in translating therapeutic advances into the clinic are discussed. Taken together, this review summarizes the status quo in gut biofilm research and provides perspectives and guidance for future research and therapeutic strategies.
Water-based skin products that are free of alcohol may include a gel or a mousse for sanitising the skin. The gel or mousse skin sanitiser may include a skin moisturiser, an antimicrobial agent and a foaming aid or a gelling agent. Preferably the composition contains an antimicrobial agent, more specifically an antibacterial. The antimicrobial is present at an amount of 0.495 to 0.88 wt %. Prefferred antibacterials are cetrimide, chlorhexidine diglutonate, benzalkonium chloride or triclosan. Also disclosed is an alcohol-free aqueous ultrasound transmitting gel.
PURPOSE: An anti-acne composition containing a germinated soybean extract and lactic acid bacteria which suppresses Propionibacterium acnes is provided to specifically suppress P. acnes which cause acne, to ensure antibacterial action against P. acne and harmful bacteria, and to prevent and treat acne diseases. CONSTITUTION: An anti-acne composition contains a germinated soybean extract and lactic acid bacteria which suppress Propionibacterium acnes. The extract is prepared using water, C1-C5 alcohols, propylene glycol, 1,3-butylene glycol, or a mixture thereof. The antibacterial composition has an antibacterial activity against one or more selected from the group consisting of E.coli, Salmonella typhimurium, Staphyllococcus aureus, Candida albican, Aspergillus niger, and Propionibacterium acnes. The lactic acid bacteria are Bipidobacterium lactobacillus SPM0308 (KCTC 11669BP). A drug, a health functional food, or a cosmetic composition contains the composition.
Nortriptyline hydrochloride is not recommended for children.

Nortriptyline hydrochloride is administered orally in the form of capsules. Lower than usual dosages are recommended for elderly patients and adolescents. Lower dosages are also recommended for outpatients than for hospitalized patients who will be under close supervision. The physician should initiate dosage at a low level and increase it gradually, noting carefully the clinical response and any evidence of intolerance. Following remission, maintenance medication may be required for a longer period of time at the lowest dose that will maintain remission.

If a patient develops minor side effects, the dosage should be reduced. The drug should be discontinued promptly if adverse effects of a serious nature or allergic manifestations occur.

Usual Adult Dose \- 25 mg three or four times daily; dosage should begin at a low level and be increased as required. As an alternate regimen, the total daily dosage may be given once a day. When doses above 100 mg daily are administered, plasma levels of nortriptyline should be monitored and maintained in the optimum range of 50 to 150 ng/mL. Doses above 150 mg/day are not recommended. 

Elderly and Adolescent Patients \- 30 to 50 mg/day, in divided doses, or the total daily dosage may be given once a day.
Subjects will follow the sit less regime during four days. Each day will consist of 9 hours sitting, 4 hours walking, 3 hours standing and 8 hours sleeping. The walking and standing will be done in a minimum of eight bouts with a time interval of \>1 hour. The subjects will be instructed to walk on a slow pace, i.e. 2-3 km/h, which is comparable to walking during shopping, walking to the office etc.
PURPOSE: An oral pharmaceutical composition containing bisphosphonic acid and an absorbing agent is provided to remarkably enhance the absorption of the bisphosphonic acid and a salt thereof into the human body and to minimize side effects. CONSTITUTION: An oral pharmaceutical composition contains bisphosphonic acid or a pharmaceutically acceptable salt thereof; and gelatin, polyvinyl acetal diethyl amino acetate; or a mixture thereof as an absorbing agent. The bisphosphonic acid is ibandronic acid, risedronic acid, alenronic acid, pamidronic acid, or zoledronic acid. The composition additionally contains citric acid, succinic acid, fumaric acid, acetic acid, phosphoric acid, sulfuric acid, or hydrochloric acid or inorganic acid. The composition also contains a surfactant or oil. [Reference numerals] (AA) Comparing formulation(Bonviva Tab.); (BB) Embodiment 11; (CC) Embodiment 12; (DD) Concentration of ibandronic acid in blood(ng/mL); (EE) Time(hr)
After the MTD is determined, additional patients will be enrolled at this dose level to ensure 14 patients evaluable for the efficacy endpoints (MPR) at the planned interim analysis. The 6 patients treated at the MTD in phase I will be included if evaluable for MPR, so that additional 8 patients will be enrolled in this stage.
The most common signs to be expected are bradycardia, congestive heart failure, hypotension, bronchospasm and hypoglycemia. In cases of massive intentional overdosage (2 to 16 grams) of sotalol hydrochloride the following clinical findings were seen: hypotension, bradycardia, cardiac asystole, prolongation of QT interval, Torsade de Pointes, ventricular tachycardia, and premature ventricular complexes. If overdosage occurs, therapy with sotalol should be discontinued and the patient observed closely. Because of the lack of protein binding, hemodialysis is useful for reducing sotalol plasma concentrations. Patients should be carefully observed until QT intervals are normalized and the heart rate returns to levels >50 bpm. The occurrence of hypotension following an overdose may be associated with an initial slow drug elimination phase (half life of 30 hours) thought to be due to a temporary reduction of renal function caused by the hypotension. In addition, if required, the following therapeutic measures are suggested: 

Bradycardia or Cardiac Asystole: Atropine, another anticholinergic drug, a beta-adrenergic agonist or transvenous cardiac pacing. 

Heart Block: (second and third degree) transvenous cardiac pacemaker. 

Hypotension: (depending on associated factors) epinephrine rather than isoproterenol or norepinephrine may be useful. 

Bronchospasm: Aminophylline or aerosol beta-2-receptor stimulant. 

Torsade de Pointes: DC cardioversion, transvenous cardiac pacing, epinephrine, magnesium sulfate.
UNLABELLED: Spartalizumab (PDR001) is a humanized IgG4 monoclonal antibody targeting programmed cell death protein 1 (PD-1). We conducted a single-arm, phase 2 trial to investigate the efficacy and safety of spartalizumab in patients with refractory esophageal squamous cell carcinoma (ESCC). Patients with histologically confirmed ESCC who experienced disease progression after platinum-based chemotherapy received 300 mg of intravenous spartalizumab every three weeks until disease progression or occurrence of unacceptable toxicity. The primary endpoint was centrally assessed objective response according to the Response Evaluation Criteria in Solid Tumors, version 1.1. Adverse events were closely monitored throughout the study. From March 2020 through April 2021, 44 patients with ESCC were enrolled. Of the 44 patients, the objective response rate was 20.5% (95% confidence interval: 8.5-32.4). With a median follow-up of 10.9 months, median progression-free survival and overall survival were 3.2 months and 11.2 months, respectively. In addition, the median duration of response was 24.7 months. The most common grade 3 or 4 adverse event was grade 3 dysphagia (eight [18%] patients). Biomarker analyses explored programmed cell death ligand 1 and CD20 as potential predictive markers for PD-1 blockade. Spartalizumab showed promising activity with a manageable safety profile, indicating its potential as a new treatment option for patients with refractory ESCC.
TRIAL REGISTRATION: The trial was registered at ClinicalTrials.gov under the identifier NCT03785496.
Patients will be seated in a comfortable reclined chair. The neurostimulation protocol will include 1-Hz rTMS over the bilateral SMA at 110% resting motor threshold (RMT). The SMA will be identified as 4 cm anterior to the vertex (Cz in standard 10-20 EEG setup). Each session will consist of 6 trains lasting 5 minutes each (300 pulses per train) with an intertrain interval of 1 minute for a total duration of 35 minutes (1800 pulses). Patients will receive 4 sessions each day on 4 consecutive days for a total of 16 sessions. Daily duration of this study protocol should last approximately 170 minutes including a 10 minute break in between each session.
The invention relates to a taxol/glucan synchronous-assembled micro/nano-fiber drug loading system and a preparation method thereof. The micro/nano-fiber drug loading system is composed of taxol and glucan which is 40,000 in average molecular weight. Drug loading micro/nano-fibers are formed as a taxol solution and a glucan solution are mixed at a volume ratio of 1 to and two molecules are cooperated and synchronously assembled in a mixed solution under the action of non-covalant bonds. In comparison with an existing taxol drug loading system, the drug loading system provided by the invention is greater than 70% in drug loading rate, and the drug loading system is stable and slow in drug release and low in toxicity on normal cells while significant in effect of killing cancer cell. The micro/nano-fibers provided by the invention, with the advantages, are safer and more effective in clinical application as the drug loading system. Furthermore, the preparation method provided by the invention has the advantages of being simple, safe and cheap in equipment, low in environmental pollution and the like. Therefore, the taxol/glucan synchronous-assembled micro/nano-fiber drug loading system has a broad application prospect in the aspect of treating cancers.
Patients with an odontogenic cervicofacial infection were treated with one dose of Solumedrol 125mg intravenous at time of surgery, as well as three consecutive doses of Solumedrol 125mg intravenous every six hours post-operatively. Remainder of management was as per protocol.